[PDF][PDF] Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321
B Barlogie, RA Kyle, KC Anderson, PR Greipp… - J Clin Oncol, 2006 - academia.edu
B Barlogie, RA Kyle, KC Anderson, PR Greipp, HM Lazarus, DD Hurd, J McCoy…
J Clin Oncol, 2006•academia.eduPurpose Results of a prospective randomized trial conducted by the Intergroupe Francais du
Myé lome (IFM 90) indicated that autologous hematopoietic cell–supported high-dose
therapy (HDT) effected higher complete response rates and extended progression-free
survial (PFS) and overall survival (OS) compared with standard-dose therapies (SDT) for
patients with multiple myeloma (MM).
Myé lome (IFM 90) indicated that autologous hematopoietic cell–supported high-dose
therapy (HDT) effected higher complete response rates and extended progression-free
survial (PFS) and overall survival (OS) compared with standard-dose therapies (SDT) for
patients with multiple myeloma (MM).
Purpose
Results of a prospective randomized trial conducted by the Intergroupe Francais du Myé lome (IFM 90) indicated that autologous hematopoietic cell–supported high-dose therapy (HDT) effected higher complete response rates and extended progression-free survial (PFS) and overall survival (OS) compared with standard-dose therapies (SDT) for patients with multiple myeloma (MM).
academia.edu